| COVID-19 |
1 |
1 |
| Idiopathic Pulmonary Fibrosis |
0 |
0.99 |
| Lung |
0 |
0.91 |
| Lung Fibrosis |
0 |
0.81 |
| Interstitial Lung Disease |
0 |
0.68 |
| Lung Transplantation |
0 |
0.59 |
| Stress |
0 |
0.24 |
| Biologic Therapy |
0 |
0.23 |
| Biomarker |
0 |
0.19 |
| Heart Failure (HF) |
0 |
0.18 |
| Cytokines |
0 |
0.14 |
| Healthcare and Medical Technology |
0 |
0.13 |
| Hypertension |
0 |
0.11 |
| Stem Cell Research and Therapy |
0 |
0.11 |
| Pulmonary Arterial Hypertension |
0 |
0.09 |
| Asthma |
0 |
0.06 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.06 |
| Tobacco Cessation |
0 |
0.06 |
| Wound Management |
0 |
0.06 |
| Artificial Intelligence |
0 |
0.05 |
| Blood |
0 |
0.05 |
| California |
0 |
0.05 |
| Clinical Research |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Heart |
0 |
0.05 |
| Immunohistochemistry |
0 |
0.05 |
| Injury |
0 |
0.05 |
| Interleukin |
0 |
0.05 |
| Molecular Medicine |
0 |
0.05 |
| Pandemic |
0 |
0.05 |
| Pathogenesis |
0 |
0.05 |
| Proton Pump Inhibitor |
0 |
0.05 |
| Pulmonary Hypertension |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Tobacco Use |
0 |
0.05 |
| Transplantation |
0 |
0.05 |